Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience

Author:

Bettoli V.1,Manfredini M.12ORCID,Calamo G.1,Forconi R.1,Bencivelli D.1,Mantovani L.1,Pellacani G.2,Corazza M.1

Affiliation:

1. Department of Medical Sciences, Section of Dermatology; University of Ferrara; Ferrara Italy

2. Department of Surgical, Medical, Dental & Morphological Sciences with Interest Transplant, Oncological & Regenerative Medicine, Dermatology Unit; University of Modena & Reggio Emilia; Modena Italy

Publisher

Wiley

Subject

Dermatology,General Medicine

Reference7 articles.

1. Infection-free clinical response among patients with hidradenitis Suppurativa who were treated with adalimumab: Results from two phase 3 studies;Giamarellos-Bourboulis;Wounds : A Compendium of Clinical Research and Practice,2017

2. Assessing the validity, responsiveness and meaningfulness of the hidradenitis Suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis Suppurativa treatment;Kimball;The British Journal of Dermatology,2014

3. Adalimumab for the treatment of moderate to severe hidradenitis Suppurativa: A parallel randomized trial;Kimball;Annals of Internal Medicine,2012

4. Two phase 3 trials of adalimumab for hidradenitis Suppurativa;Kimball;The New England Journal of Medicine,2016

5. Objective scoring of hidradenitis Suppurativa reflecting the role of tobacco smoking and obesity;Sartorius;The British Journal of Dermatology,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3